CONMED Q3: Steady Growth, Supply Chain Improvements

CONMEDs Q3 earnings show steady revenue growth, surpassing analyst expectations with $337.9 million, driven by strong orthopedics and general surgery sales. Key products like BioBrace and AirSeal platform contributed to this growth. Despite a decrease in operating margin, CONMED attributes this to improved supply chain operations and better engagement from surgeons. The company raised its full-year revenue and adjusted earnings per share guidance, with stock trading close to pre-earnings announcement price.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.